ArticleLeukemia2013

Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.

E D Warlick et al.PubMed ↗Publisher ↗

No numbers read from the abstract.